MIRNA THERAPEUTICS, INC.

Company Information

Company Name
MIRNA THERAPEUTICS, INC.
Address
2150 WOODWARD ST
AUSTIN, TX, 78744-1038
Phone
n/a
URL
n/a
DUNS
805509424
Number of Employees
n/a

Award Totals

PROGRAM/PHASE
AWARD AMOUNT ($)
NUMBER OF AWARDS
SBIR Phase I
$1,341,762.00
5
STTR Phase I
$224,996.00
1
Chart code to be here

Award List

  1. MicroRNA therapeutics for prostate cancer

    Amount: $282,967.00

    DESCRIPTION (provided by applicant): Prostate cancer (PrCa) is the most commonly diagnosed cancer in men and the second leading cause of cancer deaths in males, following only lung cancer. Despite adv ...

    SBIR Phase I 2010 Department of Health and Human Services
  2. Development of modified microRNA therapeutics

    Amount: $287,270.00

    DESCRIPTION (provided by applicant): Experimental evidence accumulated in the past few years indicates that several miRNAs likely function as tumor suppressors and that the altered expression of these ...

    SBIR Phase I 2010 Department of Health and Human Services
  3. Combination molecular therapeutics for lung cancer

    Amount: $171,527.00

    DESCRIPTION (provided by applicant): Lung cancer is the leading cause of cancer deaths in the United States with an estimated gt160,000 deaths and gt200,000 newly diagnosed cases each year. Despite th ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Systemic delivery of chitosan/miRNA nanoparticles to prostate tumors

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): MicroRNAs (miRNAs) have emerged as a promising new class of therapeutics for cancer. miRNAs are small, non-coding RNAs that determine cell fate by post-transcripti ...

    SBIR Phase I 2012 Department of Health and Human Services
  5. Therapeutic miRNAs in combination with conventional chemotherapy

    Amount: $299,999.00

    DESCRIPTION (provided by applicant): Mirna Therapeutics, a Texas-based company, is developing non-small cell lung cancer (NSCLC) therapies using tumor suppressor miRNAs. This approach, miRNA replace ...

    SBIR Phase I 2012 Department of Health and Human Services
  6. A New MicroRNA-1291 Replacement Therapy for Pancreatic Cancer Disease

    Amount: $224,996.00

    DESCRIPTION (provided by applicant): Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. There is a clear need for more effective therapies to treat deadly panc ...

    STTR Phase I 2014 Department of Health and Human Services

Agency Micro-sites


SBA logo

Department of Agriculture logo

Department of Commerce logo

Department of Defense logo

Department of Education logo

Department of Energy logo

Department of Health and Human Services logo

Department of Homeland Security logo

Department of Transportation logo

Enviromental Protection Agency logo

National Aeronautics and Space Administration logo

National Science Foundation logo
US Flag An Official Website of the United States Government